Cardiovascular disease mortality risk among patients with metastatic melanoma before and after the approval of immunotherapy in the United States: a Surveillance, Epidemiology, and End Results database-based study
Metastatic melanoma patients exhibited an elevated CVM risk after the approval of ICIs, peaking in early latency period and older population. Timely monitoring and effective interventions for cardiovascular diseases may be warranted in patients with metastatic melanoma, especially in the immunotherapy era.
Authors
- Yonghuan Wang
- Rui Yan (ORCID: https://orcid.org/0000-0002-5330-7861)
- Qiannan Wang (ORCID: https://orcid.org/0000-0001-9059-7717)
- Jinglian Li
- Jianmin Niu (ORCID: https://orcid.org/0000-0002-1182-5994)
- Yanni Jia (ORCID: https://orcid.org/0000-0002-0952-0593)
- Zhenhua Li (ORCID: https://orcid.org/0000-0002-6027-0235)
- Yufeng Zhang (ORCID: https://orcid.org/0000-0002-3154-7979)
- Sijin Li (ORCID: https://orcid.org/0000-0002-3230-5170)
- Yuanyuan Li (ORCID: https://orcid.org/0000-0002-9143-8029)
- Xiaoqin Luo (ORCID: https://orcid.org/0000-0002-3572-3909)
Institutions
- Shanxi Medical University (CN)
- First Hospital of Shanxi Medical University (CN)
Publication Details
- Journal
- European journal of medical research
- Published
- 2025-10-15
- DOI
- https://doi.org/10.1186/s40001-025-03255-2
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- National Cancer Institute